ABL Bio is seeking to transform itself from a licensing-focused biotech company into a globally competitive drug developer while advancing both its oncology pipeline and proprietary platform technologies. “The dream is no longer signing another large licensing agreement,” Lee Sang-hoon, CEO of ABL Bio, said at a press conference at the Conrad Seoul on Thursday. "The goal is building a company that can stand shoulder to shoulder with global pharmaceutical companies." The vision comes as ABL Bio e